Product: Phospho-RUNX1 / AML1 (Ser304) Antibody
Catalog: AF3379
Description: Rabbit polyclonal antibody to Phospho-RUNX1 / AML1 (Ser304)
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
Mol.Wt.: 50kDa; 49kD(Calculated).
Uniprot: Q01196
RRID: AB_2834810

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(100%), Xenopus(100%)
Phospho-RUNX1 / AML1 (Ser304) Antibody detects endogenous levels of RUNX1 / AML1 only when phosphorylated at Serine 304.
Cite Format: Affinity Biosciences Cat# AF3379, RRID:AB_2834810.
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.


Acute myeloid leukemia 1; Acute myeloid leukemia 1 protein; alpha subunit core binding factor; AML 1; AML1; AML1 EVI 1; AML1 EVI 1 fusion protein; Aml1 oncogene; AMLCR 1; AMLCR1; CBF alpha 2; CBF-alpha-2; CBFA 2; CBFA2; Core binding factor alpha 2 subunit; Core binding factor runt domain alpha subunit 2; Core-binding factor subunit alpha-2; EVI 1; EVI1; HGNC; Oncogene AML 1; Oncogene AML-1; OTTHUMP00000108696; OTTHUMP00000108697; OTTHUMP00000108699; OTTHUMP00000108700; OTTHUMP00000108702; PEA2 alpha B; PEA2-alpha B; PEBP2 alpha B; PEBP2-alpha B; PEBP2A2; PEBP2aB; Polyomavirus enhancer binding protein 2 alpha B subunit; Polyomavirus enhancer-binding protein 2 alpha B subunit; Run1; Runt related transcription factor 1; Runt-related transcription factor 1; RUNX 1; Runx1; RUNX1_HUMAN; SL3 3 enhancer factor 1 alpha B subunit; SL3-3 enhancer factor 1 alpha B subunit; SL3/AKV core binding factor alpha B subunit; SL3/AKV core-binding factor alpha B subunit;



Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood.

Core binding factor (CBF) is a heterodimeric transcription factor that binds to the core element of many enhancers and promoters.



Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q01196 As Substrate

Site PTM Type Enzyme
T14 Phosphorylation
S17 Phosphorylation
T18 Phosphorylation
S21 Phosphorylation Q00534 (CDK6) , P06493 (CDK1)
K24 Acetylation
K24 Ubiquitination
K43 Acetylation
K43 Ubiquitination
S50 Phosphorylation
S67 Phosphorylation
K83 Ubiquitination
K90 Ubiquitination
K125 Ubiquitination
K144 Ubiquitination
K167 Ubiquitination
K182 Ubiquitination
K188 Acetylation
K188 Ubiquitination
S191 Phosphorylation
S193 Phosphorylation
S199 Phosphorylation
R206 Methylation
T207 Phosphorylation
R210 Methylation
S212 Phosphorylation
T219 Phosphorylation
R223 Methylation
S225 Phosphorylation
S229 Phosphorylation
T230 Phosphorylation
S238 Phosphorylation
S249 Phosphorylation P28482 (MAPK1) , Q00534 (CDK6) , Q9H2X6 (HIPK2) , P24941 (CDK2) , P06493 (CDK1)
S253 Phosphorylation
Y254 Phosphorylation
S257 Phosphorylation
Y258 Phosphorylation
S263 Phosphorylation
S266 Phosphorylation P28482 (MAPK1) , P24941 (CDK2) , Q00534 (CDK6) , P06493 (CDK1)
S268 Phosphorylation
T273 Phosphorylation Q9H2X6 (HIPK2) , P24941 (CDK2) , P06493 (CDK1) , P28482 (MAPK1) , Q00534 (CDK6)
S276 Phosphorylation P24941 (CDK2) , P28482 (MAPK1) , P06493 (CDK1) , Q00534 (CDK6) , Q9H2X6 (HIPK2)
S292 Phosphorylation
S295 Phosphorylation
T296 Phosphorylation
R319 Methylation
S329 Phosphorylation
T331 Phosphorylation
S397 Phosphorylation P06493 (CDK1) , Q00534 (CDK6)
S423 Phosphorylation
S433 Phosphorylation
S435 Phosphorylation
Y453 Phosphorylation

Research Backgrounds


Forms the heterodimeric complex core-binding factor (CBF) with CBFB. RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters (Probable). Essential for the development of normal hematopoiesis. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the BLK promoter. Inhibits KAT6B-dependent transcriptional activation (By similarity). Involved in lineage commitment of immature T cell precursors. CBF complexes repress ZBTB7B transcription factor during cytotoxic (CD8+) T cell development. They bind to RUNX-binding sequence within the ZBTB7B locus acting as transcriptional silencer and allowing for cytotoxic T cell differentiation. CBF complexes binding to the transcriptional silencer is essential for recruitment of nuclear protein complexes that catalyze epigenetic modifications to establish epigenetic ZBTB7B silencing (By similarity). Controls the anergy and suppressive function of regulatory T-cells (Treg) by associating with FOXP3. Activates the expression of IL2 and IFNG and down-regulates the expression of TNFRSF18, IL2RA and CTLA4, in conventional T-cells. Positively regulates the expression of RORC in T-helper 17 cells (By similarity).

Isoform AML-1G shows higher binding activities for target genes and binds TCR-beta-E2 and RAG-1 target site with threefold higher affinity than other isoforms. It is less effective in the context of neutrophil terminal differentiation.

Isoform AML-1L interferes with the transactivation activity of RUNX1.


Phosphorylated in its C-terminus upon IL-6 treatment. Phosphorylation enhances interaction with KAT6A.


Phosphorylated in Ser-249 Thr-273 and Ser-276 by HIPK2 when associated with CBFB and DNA. This phosphorylation promotes subsequent EP300 phosphorylation.

Subcellular Location:


Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood.

Subunit Structure:

Heterodimer with CBFB. RUNX1 binds DNA as a monomer and through the Runt domain. DNA-binding is increased by heterodimerization. Isoform AML-1L can neither bind DNA nor heterodimerize. Interacts with TLE1 and ALYREF/THOC4. Interacts with ELF1, ELF2 and SPI1. Interacts via its Runt domain with the ELF4 N-terminal region. Interaction with ELF2 isoform 2 (NERF-1a) may act to repress RUNX1-mediated transactivation. Interacts with KAT6A and KAT6B. Interacts with SUV39H1, leading to abrogation of transactivating and DNA-binding properties of RUNX1. Interacts with YAP1. Interacts with HIPK2 (By similarity). Interaction with CDK6 prevents myeloid differentiation, reducing its transcription transactivation activity. Found in a complex with PRMT5, RUNX1 and CBFB. Interacts with FOXP3. Interacts with TBX21 (By similarity). Interacts with DPF2.


A proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes.

Research Fields

· Cellular Processes > Cellular community - eukaryotes > Tight junction.   (View pathway)

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Transcriptional misregulation in cancer.

· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Acute myeloid leukemia.   (View pathway)

· Organismal Systems > Immune system > Th17 cell differentiation.   (View pathway)

Restrictive clause


Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.